welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Upcoming events – pivotal data loom for Novavax and Mallinckrodt
Welcome to your weekly digest of approaching regulatory and clinical readouts. Novavax is up 4% today thanks to topline results from a phase II trial showing that its Nanoflu influenza vaccine caused “vigorous immune responses” to four strains of flu, and that these responses were enhanced when the group’s Matrix-M adjuvant was added to the vaccine.
But an even more meaningful event is approaching. Novavax’s lead asset, a vaccine against respiratory syncytial virus, is in phase III, and after its disastrous failure two years ago in a study that was intended to be pivotal this is its last chance.
Resvax, also known as RSV F Vaccine since it targets the fusion protein of the virus, crashed out of the Resolve trial, testing it in prevention of moderate to severe RSV-associated lower respiratory tract disease, in mid-2016.
expertly curated content related to this topic
-
How to Defy a Hereditary Predisposition and Prevent Colon Cancerhttps://www.youtube.com/watch?v=IynYbT2i...
-
Long-term Results After Restorative Proctocolectomy With Ileal Pouch-Anal Anastomosis at a Young AgeBACKGROUND: Restorative proctocolectomy...
-
Judy E. Garber, MD, MPHDr. Garber received her MD and MPH in 19...
-
High-Dose Tamoxifen and Sulindac as First-Line Treatment for Desmoid TumorsBACKGROUND : Desmoid tumors are mesenchy...
-
Patient Information: Colon and Rectal Cancer Screening (Beyond the Basics)Colorectal cancer develops in the large ...
-
Colon Polyps and the Prevention of Colorectal CancerThis book explains colon polyps and thei...
-
Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates P...Cancer Prevention Pharmaceuticals, Inc. ...